Abstract
Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.
Keywords: Colorectal cancer (CRC), inflammatory bowel disease (IBD), mesalazine, molecular pathways, EGFR
Current Cancer Therapy Reviews
Title: Molecular Targets of Mesalazine in Colorectal Cancer
Volume: 4 Issue: 4
Author(s): Carmine Stolfi, Roberto Pellegrini, Francesco Pallone and Giovanni Monteleone
Affiliation:
Keywords: Colorectal cancer (CRC), inflammatory bowel disease (IBD), mesalazine, molecular pathways, EGFR
Abstract: Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.
Export Options
About this article
Cite this article as:
Stolfi Carmine, Pellegrini Roberto, Pallone Francesco and Monteleone Giovanni, Molecular Targets of Mesalazine in Colorectal Cancer, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413326
DOI https://dx.doi.org/10.2174/157339408786413326 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Current Cancer Drug Targets The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Fatty Acid (FA) Compositions and Trans Content of Frequently Consumed Edible Oils and Fats from Iran’ Market
Current Nutrition & Food Science Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin
Current Drug Targets Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Metabolomics as a Tool for Drug Discovery and Personalised Medicine. A Review
Current Topics in Medicinal Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Nutrition and DNA Repair - Potential Molecular Mechanisms of Action
Current Cancer Drug Targets Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Recent Patents on Anti-Cancer Drug Discovery Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Association of Genetic Variants with Colorectal Cancer in the Extended MENA Region: A Systematic Review
Current Molecular Medicine Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design